Healthpeak (DOC) Turns Portfolio Sales Into Fatter 2026 Guidance
Healthpeak Properties (DOC) raised its 2026 guidance, citing strong performance in outpatient medical and lab leasing, and significant growth at its senior housing operator, Janus Living (JAN). The company reported $0.46 FFO per share, flat year-over-year, and used asset sales to reduce debt and fund buybacks. Lab segment NOI declined, and leverage remains at 4.7x EBITDAre.
How this was made
The 30-second read
Why it matters
The guidance raise signals stronger earnings potential, but mixed segment performance and leverage warrant caution.
Market read
Guidance lift and strong subsidiary performance could drive Healthpeak stock higher, while sector peers may see spillover effects.
What to watch
High leverage (4.7x) and dependence on disposals could constrain future cash flow.
Background
Healthpeak Properties reported Q2 results, raised 2026 guidance, and detailed portfolio activity including a $1.025 bn asset sale and a new $500 m buyback.
Ticker impact
Healthpeak Properties raised its full-year 2026 guidance to $0.48‑$0.52 EPS after Q2 results.
Potential upside of 5‑8% on near‑term trading.
Guidance increase is material and new; investors may reprice expectations.
Janus Living, 73.6% owned by Healthpeak, posted 45% revenue growth and $1 bn acquisitions.
May boost Healthpeak’s share price; limited direct impact on JAN.
Janus Living’s results are disclosed for the first time and reinforce the parent’s guidance.
Market effects
Positive for healthcare REIT sector as earnings guidance improves.
U.S. REIT investors may reallocate toward health‑care properties.
Limited to U.S. REIT and senior‑housing markets.
Counterpoint
Guidance lift may be offset by lab segment weakness and reliance on asset sales.
Key entities
- CompanyHealthpeak Properties
Healthcare real‑estate REIT (ticker DOC).
- CompanyJanus Living
Senior‑housing operator (ticker JAN) majority‑owned by Healthpeak.